Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
Daliresp
National Institutes of Health
Create Alert
Related topics
Related topics
1 relation
Broader (1)
Roflumilast
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Roflumilast: A Review in COPD
K. P. Garnock-jones
Drugs
2015
Corpus ID: 29862692
Roflumilast (Daliresp®, Daxas®) is a selective phosphodiesterase 4 (PDE4) inhibitor that decreases systemic and pulmonary…
Expand
2014
2014
Roflumilast (Daliresp) for chronic obstructive pulmonary disease
O. Bazaldua
,
D. Davidson
,
Franklyn C. Babb
2014
Corpus ID: 78608553
Roflumilast therapy has a limited role in patients with severe COPD, and no role in patients with mild to moderate COPD. It will…
Expand
2013
2013
Spectra studies of the structural identification of the new drug daliresp
Song Ai-hu
2013
Corpus ID: 100949060
Objective To identify the structure of the new drug daliresp. Methods The structure of daliresp w as identified by UV,IR,MS,1H…
Expand
2013
2013
Roflumilast ( Daliresp ® ) : A Selective Phosphodiesterase-4 Inhibitor for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Holly A. Smith
2013
Corpus ID: 36536931
APIXABAN (ELIQUIS®) FOR ORAL ANTICOAGULATION IN NONVALVULAR ATRIAL FIBRILLATION hronic obstructive pulmonary disease (COPD) is a…
Expand
Review
2013
Review
2013
Roflumilast in the management of chronic obstructive pulmonary disease.
Melissa Lipari
,
H. Benipal
,
Pramodini B Kale-Pradhan
American journal of health-system pharmacy : AJHP…
2013
Corpus ID: 35586832
PURPOSE The pharmacology, pharmacokinetics, efficacy, and safety of roflumilast-the first in a new class of agents for managing…
Expand
2012
2012
Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
J. Baye
P & T : a peer-reviewed journal for formulary…
2012
Corpus ID: 30328613
Chronic obstructive pulmonary disease (COPD) is characterized by a gradual and progressive loss of lung function. The consensus…
Expand
2012
2012
Roflumilast ( Daliresp ) A Novel Phosphodiesterase-4 Inhibitor for the Treatment Of Severe Chronic Obstructive Pulmonary Disease DRUG FORECAST
Roflumilast Daliresp
,
Drug Forecast
2012
Corpus ID: 41431929
is substantial. Quality of life, morbidity, and mortality are all negatively affected by the disease. In the National Health and…
Expand
2011
2011
Roflumilast (Daliresp) for COPD.
The Medical letter on drugs and therapeutics
2011
Corpus ID: 13234119
Review
2011
Review
2011
Roflumilast for the treatment of respiratory disease: review of the Phase II and III trials
S. Antoniu
2011
Corpus ID: 26675613
Roflumilast (Daxas® [EU], Daliresp® [USA]) is the first phosphodiesterase 4 inhibitor approved in Europe to be used in severe…
Expand
2011
2011
Roflumilast, indacaterol maleate, and abiraterone acetate.
D. Hussar
,
Jeanine DePasquale
Journal of the American Pharmacists Association…
2011
Corpus ID: 39919556
roflumilast Chronic obstructive pulmonary disease (COPD) is a progressive, irreversible lung disease that is often associated…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE